Biomedical Innovation in India: With a Comparison to China and Others |
From inside the book
Results 1-5 of 43
Page
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Page 11
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Page 13
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Page 15
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Page 16
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Contents
Abbreviations | 9 |
Introduction | 15 |
Choice of Institution | 31 |
Institutions in Health and the Therapeutic | 59 |
A CrossCountry Comparison | 95 |
Capability and Research of Indian Organizations | 133 |
As Product of Drug | 211 |
States of affairs in India2 | 231 |
Possibility of biomedical innovation in India | 242 |
| 253 | |
| 273 | |
Common terms and phrases
AIIMS alliances appears areas Banerjee Bangalore Biocon bioinformatics biomedical innovation biotechnology body Bose Institute cancer capability chemical Chennai China cities collaborations competing competition consumption contesting institutions Contrarily contribution countries credibility database defined Delhi devices Distribution of publications doctor domestic dominant organization drug firms example exhibits expenditure fact failed Figure followed funding future genetic global governance groups healthcare hospital institution Hyderabad IISc important importantly increasing India India and China individual Israel journals knowledge assets Kolkata large number Lucknow major organizations Malaria manpower Medical & Hospitals mental models modes molecular biology Mumbai nanotechnology non-medical norms number of publications observed organizational organized research Orsenigo outcome output person pharmaceutical pharmaceutical firms physicians pool possibly production profit property rights Pune research assets rights to assets ScienceDirect share similar theory therapeutic transactions types voting
Popular passages
Page 258 - The Pharmaceutical Industry in the Twentieth Century: A Reappraisal of the Sources of Innovation," History and Technology 13 (1996): 83-100.
Page 257 - GPPisano. 2000. Learning new technical and interpersonal routines in operating room teams: the case of minimally invasive cardiac surgery. In Research on Managing Groups and Teams, Volume 3, JAI Press Inc.: 29-51.
Page 258 - Physicians' Views of the Relative Importance of Thirty Medical Innovations," Health Affairs, September/October 2001.
Page 257 - Industrial groups and territories: the case of MatraMarconi-Space in Toulouse', Cambridge Journal of Economics.
Page 254 - Defining the balance of risk and benefit in the era of genomics and proteomics.
Page 254 - Burt, RS (2001). Structural holes versus network closure as social capital.
Page 258 - Brett Frischmann, Innovation and Institutions: Rethinking the Economics of US Science and Technology Policy, 24 VT.